ABBV vs GILD: AbbVie and Gilead Sciences compared
The short version
From the latest prices and each company's SEC filings. Who's ahead on each measure, not which to buy.
- AbbVie is the larger company, worth $492.9B, about 2.7 times Gilead Sciences.
- Gilead Sciences grew revenue faster over the last year (+10.2% vs +10.2%).
- AbbVie keeps more of each dollar of revenue as operating profit (26.2% vs -8.2%).
- On earnings, Gilead Sciences is the cheaper stock (20.2x vs 78.1x).
- AbbVie's price assumes faster free cash flow growth: about 9% a year, against 5% for Gilead Sciences (reverse DCF).
Side by side
The stronger figure is shaded where higher (or, for valuation multiples, lower) reads as better. How the implied growth works.
| Measure | ABBV | GILD |
|---|---|---|
| Market cap | $492.9B | $184.1B |
| Share price | $276.47 | $151.17 |
| Revenue (last fiscal year) | $61.2B | $29.4B |
| Free cash flow (last fiscal year) | $17.8B | $9.5B |
| Revenue growth, last year | +10.2% | +10.2% |
| Revenue growth per year, last 5 fiscal years | +2.1% | +1.9% |
| Operating margin | 26.2% | -8.2% |
| Net margin | 9.8% | -10.6% |
| Return on equity | — | -27.4% |
| P/E (trailing) | 78.1x | 20.2x |
| Price / free cash flow | 27.7x | 19.5x |
| EV / EBITDA | 27.7x | — |
| FCF growth the price implies | 9.2% | 4.6% |
| Dividend yield | 2.4% | 2.2% |
| Debt / equity | — | 3.18x |
| Fundamental grade | C | D |
| Superinvestors holding it | 10 | 7 |
| Insider purchases, last 12 months | 6 | 4 |
Results from SEC filings
Revenue and free cash flow by fiscal year, from each company's 10-K filings.
AbbVie
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $56.2B | $22.0B | 31.9% |
| 2022 | $58.1B | $24.2B | 31.2% |
| 2023 | $54.3B | $22.1B | 23.5% |
| 2024 | $56.3B | $17.8B | 16.2% |
| 2025 | $61.2B | $17.8B | 24.6% |
Gilead Sciences
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $27.3B | $10.8B | 36.3% |
| 2022 | $27.3B | $8.3B | 26.9% |
| 2023 | $27.1B | $7.4B | 28.0% |
| 2024 | $28.8B | $10.3B | 5.8% |
| 2025 | $29.4B | $9.5B | 34.0% |
Where the revenue comes from
AbbVie · by regions, 2025
United States$46.6B76%
All other countries$5.8B9%
Germany$1.7B3%
Japan$1.3B2%
Canada$1.2B2%
China$1.0B2%
Gilead Sciences · by products, 2025
Biktarvy$14.3B49%
Descovy$2.8B9%
Genvoya$1.5B5%
Yescarta$1.5B5%
Trodelvy$1.4B5%
Sofosbuvir/Velpatasvir$1.3B4%
Compare them in fullFifteen years of statements, quarterly results, DCF and IRR models, and any number of peers side by side.
Open ABBV in InvestinglyQuestions
Which is bigger, AbbVie or Gilead Sciences?
AbbVie (ABBV), at $492.9B against $184.1B.
Is ABBV or GILD cheaper?
By trailing P/E, Gilead Sciences (20.2x) is cheaper than AbbVie (78.1x). A lower multiple can also mean the market expects less growth.
Which grows faster, ABBV or GILD?
Gilead Sciences: revenue grew +10.2% over the last year, against +10.2%.
Prices and ratios as of the last daily update; statements from SEC filings. Information only, not investment advice.